drugset / Trial / NCT00784420

Drug Interaction Study Between Raltegravir And UK-453,061

NCT00784420

Phase 1 Completed 18 enrolled Pfizer
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to estimate the effect of steady state raltegravir on the steady state pharmacokinetics of UK-453,061 and steady state UK-453,061 on the steady state pharmacokinetics of raltegravir.

Timeline

Start
2008-09
Primary completion
2008-11
Completion
2008-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Lersivirine Small molecule 1000 mg
Subject Raltegravir Other / unclassified 400 mg

Indications

No indication recorded.